Table 1.

Motolimod treatment reduces the levels of mMDSC in PBMC

	167 nM Motolimod	500 nM Motolimod
	Mean ± SE	Mean ± SE
	(n = 15)	(n = 15)
HLA‐DR–CD14+ mMDSC % among PBMCs	42.9 ± 10.3	23.1 ± 4.2
HLA‐DR–CD14+ CD33+ mMDSC % among PBMCs	44.6 ± 14.8	16.3 ± 3.7
Lin‐HLA‐DR–CD33+ gMDSC % among PBMCs	75.5 ± 27.0	57.6 ± 12.6
Lin‐HLA‐DR–CD33+ CD11b+ gMDSC % among PBMCs	84.1 ± 29.3	57.0 ± 15.0

The numbers above show the percentage reduction of MDSC among PBMCs as compared to PBS control.